Lv5
1210 积分 2025-05-16 加入
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
4个月前
已完结
Les formes rares de cancer du poumon
4个月前
已关闭
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
4个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
6个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
6个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
6个月前
已完结
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC)
6个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
6个月前
已完结
B-9-8, a Novel Harman Dimer, Reverses ABCG2-mediated Chemotherapeutic Drug Resistance
6个月前
已完结
TDP1 represents a promising therapeutic target for overcoming tumor resistance to chemotherapeutic agents: Progress and potential
6个月前
已完结
皖公网安备34019202002308
